Lung Fibrosis Pipeline Analysis 2026

Report Coverage

The Lung Fibrosis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into lung fibrosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for lung fibrosis. The Lung Fibrosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The lung fibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with lung fibrosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to lung fibrosis.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Lung Fibrosis Pipeline Outlook

Lung fibrosis is a chronic, progressive lung disorder characterized by scarring and thickening of lung tissue, leading to reduced oxygen exchange. It occurs when repeated injury or inflammation triggers abnormal wound-healing responses, causing excessive collagen deposition and stiffening of the lungs, which progressively impairs respiratory function and may lead to respiratory failure.

Lung fibrosis is managed using antifibrotic therapy, oxygen therapy, pulmonary rehabilitation, and lung transplantation in advanced cases to slow disease progression, improve breathing capacity, and enhance quality of life management. In December 2025, the United States Food and Drug Administration (US FDA) approved JASCAYD (nerandomilast), a preferential phosphodiesterase 4B inhibitor, for progressive pulmonary fibrosis. Clinical data from FIBRONEER-ILD demonstrated reduced decline in forced vital capacity, highlighting its immunomodulatory and antifibrotic benefits in lung fibrosis treatment.

Lung Fibrosis Epidemiology

According to R.G. Carbone et al., 2025, approximately 32,500 individuals in the United Kingdom are living with idiopathic pulmonary fibrosis (IPF), with a prevalence of 50 per 100,000 inhabitants. The Lung Fibrosis Pipeline is driven by rising incidence, with nearly 6,000 new cases annually in the United Kingdom and increasing global rates across regions. As per studies, adjusted incidence ranges from 0.9–13 per 100,000 globally, while prevalence is steadily rising. Median survival remains 4.5 years, with a standardized mortality ratio of 4.66, highlighting strong unmet need in fibrosis treatment and advanced therapeutic development.

Lung Fibrosis – Pipeline Therapeutic Assessment

Lung Fibrosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, at 47%, covers a major share of the total lung fibrosis clinical trials with strong clinical advancement. Phase I is at 22% supporting early-stage development, phase III at 18% enabling late-stage validation, early phase I at 7% driving initial discovery, and phase IV at 6% providing post-marketing evidence, collectively enhancing innovation and market expansion.

Lung Fibrosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the lung fibrosis pipeline analysis include small. The Lung Fibrosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for lung fibrosis. Targeted drug therapies in the pipeline are advancing with novel mechanisms aimed at slowing disease progression and improving pulmonary function. For instance, the emerging TNIK inhibitor rentosertib represents an AI-discovered approach that modulates fibrotic signaling pathways in idiopathic pulmonary fibrosis (IPF). Moreover, other investigational antifibrotic agents are being evaluated to reduce lung tissue scarring and preserve respiratory capacity.

Lung Fibrosis Clinical Trials – Key Players

The EMR report for the lung fibrosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed lung fibrosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in lung fibrosis clinical trials:

• Bristol-Myers Squibb
• Contineum Therapeutics
• Haisco Pharmaceutical Group Co., Ltd.
• Beijing Tide Pharmaceutical Co., Ltd.
• AbbVie
• Mediar Therapeutics
• Regend Therapeutics
• siRNAgen Therapeutics Inc.
• Genosco Inc.
• Avalyn Pharma Inc.
• Calluna Pharma AS
• Boehringer Ingelheim

Lung Fibrosis – Emerging Drugs Profile

Key Questions Answered in the Lung Fibrosis Pipeline Insight Report

• Which companies/institutions are leading the lung fibrosis drug development?
• Which company is leading the lung fibrosis pipeline development activities?
• What is the current lung fibrosis commercial assessment?
• What are the opportunities and challenges present in the lung fibrosis pipeline landscape?
• What is the efficacy and safety profile of lung fibrosis pipeline drugs?
• Which company is conducting major trials for lung fibrosis drugs?
• Which companies/institutions are involved in lung fibrosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in lung fibrosis?

Reasons To Buy This Report

The Lung Fibrosis pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for lung fibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into lung fibrosis collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Idiopathic Pulmonary Fibrosis Treatment Market

Progressive Pulmonary Fibrosis Pipeline Analysis Report